Trimeris Inc. (NASDAQ:TRMS) is feeling a little after-hour pressure. Roche and Trimeris today provided an update on their combined efforts to offer a needle-free device which has been investigated for use with FUZEON® (enfuvirtide).
Based on comprehensive assessment of the clinical program, as well a significant delay in achieving U.S. regulatory approval due to the time required to generate additional data, Roche and Trimeris are withdrawing a supplemental application for approval to market the Biojector® 2000 device.
This device is known as “B2000” and is manufactured by Bioject Medical Technologies, Inc. (NASDAQ:BJCT) for use with FUZEON. Importantly, Roche and Trimeris believe that patients who are currently administering FUZEON with the device through an existing program or clinical trial may continue to do so, provided that the precautions in the current FUZEON label regarding use with B2000 are followed. Roche and Trimeris noted that they recognize that B2000 is commercially available for general use.
There is no activity seen in BJCT shares. Trimeris (TRMS) originally saw a 10% drop in after-hours, but now shares are are down only about 4% at $7.82. Shares were up almost 4% in regualar trading to close at $8.21 today. Trimeris has a $182 million market cap and it is actually profitable. This may be a negative headline, but it has other oars in the water. Over the last year shares have traded as as low as $5.34 and as high as $13.85.
Jon C. Ogg
October 3, 2007
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.